These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 10381769)

  • 1. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.
    Mas M; Farré M; de la Torre R; Roset PN; Ortuño J; Segura J; Camí J
    J Pharmacol Exp Ther; 1999 Jul; 290(1):136-45. PubMed ID: 10381769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.
    Harris DS; Baggott M; Mendelson JH; Mendelson JE; Jones RT
    Psychopharmacology (Berl); 2002 Aug; 162(4):396-405. PubMed ID: 12172693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans.
    Pacifici R; Zuccaro P; Hernandez López C; Pichini S; Di Carlo S; Farré M; Roset PN; Ortuño J; Segura J; Torre RL
    J Pharmacol Exp Ther; 2001 Jan; 296(1):207-15. PubMed ID: 11123382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers.
    Dumont GJ; Schoemaker RC; Touw DJ; Sweep FC; Buitelaar JK; van Gerven JM; Verkes RJ
    J Psychopharmacol; 2010 Feb; 24(2):155-64. PubMed ID: 19164498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethanol co-administration moderates 3,4-methylenedioxymethamphetamine effects on human physiology.
    Dumont GJ; Kramers C; Sweep FC; Willemsen JJ; Touw DJ; Schoemaker RC; van Gerven JM; Buitelaar JK; Verkes RJ
    J Psychopharmacol; 2010 Feb; 24(2):165-74. PubMed ID: 19074534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart.
    Farré M; Tomillero A; Pérez-Mañá C; Yubero S; Papaseit E; Roset PN; Pujadas M; Torrens M; Camí J; de la Torre R
    Eur Neuropsychopharmacol; 2015 Oct; 25(10):1637-49. PubMed ID: 26073279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the α₂-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers.
    Hysek CM; Brugger R; Simmler LD; Bruggisser M; Donzelli M; Grouzmann E; Hoener MC; Liechti ME
    J Pharmacol Exp Ther; 2012 Feb; 340(2):286-94. PubMed ID: 22034656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers.
    Baggott MJ; Garrison KJ; Coyle JR; Galloway GP; Barnes AJ; Huestis MA; Mendelson JE
    J Psychoactive Drugs; 2019; 51(2):108-117. PubMed ID: 30967099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
    McNamara R; Kerans A; O'Neill B; Harkin A
    Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans.
    Hysek CM; Simmler LD; Ineichen M; Grouzmann E; Hoener MC; Brenneisen R; Huwyler J; Liechti ME
    Clin Pharmacol Ther; 2011 Aug; 90(2):246-55. PubMed ID: 21677639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of MDMA in humans.
    de la Torre R ; Farré M; Roset PN; Lopez CH; Mas M; Ortuño J; Menoyo E; Pizarro N; Segura J; Cami J
    Ann N Y Acad Sci; 2000 Sep; 914():225-37. PubMed ID: 11085324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Pharmacology of Mephedrone in Comparison with MDMA.
    Papaseit E; Pérez-Mañá C; Mateus JA; Pujadas M; Fonseca F; Torrens M; Olesti E; de la Torre R; Farré M
    Neuropsychopharmacology; 2016 Oct; 41(11):2704-13. PubMed ID: 27206266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.
    O'Mathúna B; Farré M; Rostami-Hodjegan A; Yang J; Cuyàs E; Torrens M; Pardo R; Abanades S; Maluf S; Tucker GT; de la Torre R
    J Clin Psychopharmacol; 2008 Oct; 28(5):523-9. PubMed ID: 18794647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.
    Dumont GJ; Sweep FC; van der Steen R; Hermsen R; Donders AR; Touw DJ; van Gerven JM; Buitelaar JK; Verkes RJ
    Soc Neurosci; 2009; 4(4):359-66. PubMed ID: 19562632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpretation of a 3,4-methylenedioxymethamphetamine (MDMA) blood level: discussion by means of a distribution study in two fatalities.
    De Letter EA; Bouche MP; Van Bocxlaer JF; Lambert WE; Piette MH
    Forensic Sci Int; 2004 May; 141(2-3):85-90. PubMed ID: 15062945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses.
    Mueller M; Peters FT; Maurer HH; McCann UD; Ricaurte GA
    J Pharmacol Exp Ther; 2008 Oct; 327(1):38-44. PubMed ID: 18591215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.
    Farré M; Abanades S; Roset PN; Peiró AM; Torrens M; O'Mathúna B; Segura M; de la Torre R
    J Pharmacol Exp Ther; 2007 Dec; 323(3):954-62. PubMed ID: 17890444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA).
    Fonsart J; Menet MC; Debray M; Hirt D; Noble F; Scherrmann JM; Declèves X
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):339-47. PubMed ID: 19781562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics.
    Riba J; Valle M; Urbano G; Yritia M; Morte A; Barbanoj MJ
    J Pharmacol Exp Ther; 2003 Jul; 306(1):73-83. PubMed ID: 12660312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of co-administration of 3,4-methylenedioxymethamphetamine ("ecstasy") or para-methoxyamphetamine and moclobemide at elevated ambient temperatures on striatal 5-HT, body temperature and behavior in rats.
    Stanley N; Salem A; Irvine RJ
    Neuroscience; 2007 Apr; 146(1):321-9. PubMed ID: 17306465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.